Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study

By sjmartinez • May 19, 2025

Krebs MG, Cho BC, Hiret S, Han JY, Lee KH, Llácer Pérez C, De Braud F, Haura EB, Sanborn RE, Yang JC, Shu CA, Goto K, Nishio M, Zhao J, Wang Z, Tomasini P, Felip E, Goldman JW, Ou SI, Boyer M, Gao G, Qu S, Curtin JC, Lyu X, Schnepp RW, Kim P, Thayu M, Knoblauch RE, Lorenzini P, Baig M, Spira AI, Leighl NB. Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study. J Thorac Oncol. 2025 May 16:S1556-0864(25)00720-8. doi: 10.1016/j.jtho.2025.05.012. Epub ahead of print. PMID: 40383434.

Tags: advanced non-small cell lung cancer, amivantamab, CHRYSALIS, Hematology/Oncology, MET exon 14 skipping mutation, prior MET therapies, Publications

Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma

Brady MR, Matulionis N, Christofk HR, Garon EB, Lisberg A, Shackelford DB, Momcilovic M. Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous[...]

CD146+ pericyte-like lung cancer brain metastatic stem cells promote tumor angiogenesis through dual regulatory effects on the VEGF/VEGFR axis

Liu W, Duan W, Xia S, Liu Y, Chu H, Liang K, Fang S, Lin M, Wei S, You X, Hu Q, Qi J, Wang[...]

Phosphatidylserine receptors TIM-1 and AXL mediate tick-borne Powassan virus entry

Daskou M, Zaiss AK, Jeyachandran AV, Takano KA, Kan RL, Paravastu R, Gerald E, Satheeshkumar N, Rios-Rodriguez J, Russell B, Brault AC, Bhaduri A, Garcia[...]